<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02675153</url>
  </required_header>
  <id_info>
    <org_study_id>RAPA-CN-160122</org_study_id>
    <nct_id>NCT02675153</nct_id>
  </id_info>
  <brief_title>To Evaluate the Efficacy and Safety of Sirolimus for Crohn's Disease With Stenosis</brief_title>
  <official_title>Efficacy and Safety of Sirolimus in the Treatment of Crohn's Disease With Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Second Hospital of Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xijing Hospital of Digestive Diseases</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Second Hospital of Nanjing Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Crohn's disease （CD） with stenosis has limited therapeutic options and with high surgical
      rate. The present clinical trial aims to evaluate the efficacy and safety of sirolimus in the
      treatment of stricturing Crohn's Disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Management of Crohn's disease （CD） with stenosis is challenging and often requires endoscopic
      dilatation or surgical resection of the strictured bowel. Sirolimus (rapamycin), a
      macrocyclic antibiotic with immunosuppressive and antineoplastic properties, has been
      reported as promising rescue therapy for refractory CD. This study aims to evaluate the use
      of sirolimus for stricturing Crohn's Disease. Patients in this study will receive a
      continuous dosing schedule of oral sirolimus 2mg daily for six months and follow-up for at
      least one year. The Harvey-Bradshaw Index （HBI） score, Blood tests , MRI and endoscopy will
      be used to assess participants at study start and at follow-up points.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 1, 2015</start_date>
  <completion_date type="Anticipated">December 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical remission defined as HBI score ≦ 4 to measure Clinical response</measure>
    <time_frame>one year</time_frame>
    <description>The Harvey-Bradshaw Index (HBI) is used to assess the degree of illness in individuals with Crohn's disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of stenosis assessed by Magnetic Resonance Imaging</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement of stenosis assessed by Endoscopy</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>one year</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Crohn's Diseases</condition>
  <arm_group>
    <arm_group_label>Sirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects receive a continuous dosing schedule of oral sirolimus 2mg daily for six months and follow-up for at least one year.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>Sirolimus 2mg daily will be given to subjects by oral for six months.</description>
    <arm_group_label>Sirolimus</arm_group_label>
    <other_name>Rapamycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-ASA, Prednisone, Azathioprine or Remicade</intervention_name>
    <description>5-ASA, Prednisone, Azathioprine and Remicade are traditional treatments according to associated guidelines</description>
    <arm_group_label>Sirolimus</arm_group_label>
    <other_name>Mesalamine</other_name>
    <other_name>Corticoids</other_name>
    <other_name>Immunomodulatory therapy</other_name>
    <other_name>Infliximab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  moderate to severe Crohn's Disease (basic HBI ≥ 7) with stenosis

        Exclusion Criteria:

          -  Allergic to sirolimus or serious side effects

          -  Need emergency surgery

          -  Accompanied with other severe disease (involve C.diff infection)

          -  Follow-up less than 1 year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Faming Zhang, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Faming Zhang, MD,PhD</last_name>
    <phone>086-25-58509883</phone>
    <email>fzhang@njmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faming Zhang, MD, PhD</last_name>
      <phone>086-25-58509883</phone>
      <email>fzhang@njmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Mutalib M, Borrelli O, Blackstock S, Kiparissi F, Elawad M, Shah N, Lindley K. The use of sirolimus (rapamycin) in the management of refractory inflammatory bowel disease in children. J Crohns Colitis. 2014 Dec;8(12):1730-4. doi: 10.1016/j.crohns.2014.08.014. Epub 2014 Sep 18.</citation>
    <PMID>25240477</PMID>
  </reference>
  <reference>
    <citation>Massey DC, Bredin F, Parkes M. Use of sirolimus (rapamycin) to treat refractory Crohn's disease. Gut. 2008 Sep;57(9):1294-6. doi: 10.1136/gut.2008.157297.</citation>
    <PMID>18719139</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2016</study_first_submitted>
  <study_first_submitted_qc>February 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2016</study_first_posted>
  <last_update_submitted>June 6, 2017</last_update_submitted>
  <last_update_submitted_qc>June 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Second Hospital of Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>Faming Zhang</investigator_full_name>
    <investigator_title>Associate professor, Gastroenterology</investigator_title>
  </responsible_party>
  <keyword>Inflammatory Bowel Disease</keyword>
  <keyword>stenosis</keyword>
  <keyword>sirolimus</keyword>
  <keyword>rapamycin</keyword>
  <keyword>stricture</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

